03.26.24 -- FDA's 2024 Regulatory Outlook Recap

As cell therapies develop and become more commercialized, manufacturers must adopt a sophisticated supply chain that provides the necessary materials and technologies to support therapeutic development.

Serum-free media may yield lower CAR-T efficacies, so understanding how to optimize the media to improve the therapy is a necessary step.

Single-use tech suppliers must align with advanced therapy manufacturers to de-risk manufacturing processes and chemical composition requirements to maintain the safety and efficacy of new treatments.

The growing mRNA vaccine market ― projected to reach $127.3 billion by 2027 ― is fueling high demand for mRNA, which has resulted in a critical need to address mRNA manufacturing bottlenecks.

Demands for flexible, scalable, and cost-effective manufacturing are prompting cell and gene therapy manufacturers and CDMOs to implement single-use technology for manufacturing their therapies.

Explore a demonstration of a 250mL bioreactor system designed to run off-site in the cloud, as well as the results of its use in both cell culture and fermentation applications.

For many applications, cutting-edge centrifugation technologies can achieve cell harvest optimization, providing a low-shear, high-yield process that is tightly controlled and highly reproducible.

Stirred-tank bioreactors have emerged in recent years as the optimal platform to optimize (stem) cell culturing, raising their potential in the cell and gene therapy industry.

What are cell and gene therapies and how has the invention of CRISPR revolutionized the industry? Learn about the history of these therapies and life-changing treatments on the horizon.

Discover how products developed to tackle the absence of consistent reference material for cell-based assays in drug development became a successful solution.

Unearth best aseptic practices for cell and gene therapy production that will be foundational to the ongoing development of these therapies as well as their successful manufacturing operations.